Replies to post #7918 on Halozyme Therapeutics Inc (HALO)

[stockrafter]

Keeping me on my toes, and confused. Sorry about that.

Guess I was right the first time, knew it, but got confused, a little dyslectic I guess.

Back to it being Alteogen....

"Merck has more recently been highlighting the convenience of three as well as six-week dosing, and for the latter use it has co-formulated Keytruda with a recombinant hyaluronidase coded MK-5180."

"A subcutaneous answer to PD-1’s patent problem" 18 August 2023

https://www.oncologypipeline.com/apexonco/subcutaneous-answer-pd-1s-patent-problem